Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon alpha Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
- Author:
Fahmy T ALI
1
;
Mohamed A M ALI
;
Mayada M A ELGIZAWY
;
Ahmed M ELSAWY
Author Information
- Publication Type:Original Article
- Keywords: Chronic hepatitis C; Interferons; Response; Secreted phosphoprotein 1; Single nucleotide polymorphisms
- MeSH: Adult; Antiviral Agents/*therapeutic use; Biomarkers/blood; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus/drug effects/genetics; Hepatitis C, Chronic/*drug therapy/virology; Humans; Interferon-alpha/*therapeutic use; Male; Middle Aged; Osteopontin/*genetics; Polyethylene Glycols/*therapeutic use; Polymorphism, Single Nucleotide/genetics; Predictive Value of Tests; *Promoter Regions, Genetic; Recombinant Proteins/therapeutic use; Ribavirin/*therapeutic use; Treatment Outcome
- From:Gut and Liver 2015;9(4):516-524
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: The T-helper 1 (TH1) immune reaction is essential for the eradication of hepatitis C virus (HCV) during pegylated interferon alpha (PEG-IFN-alpha)- and ribavirin (RBV)-based therapy in chronic HCV patients. Secreted phosphoprotein 1 (SPP1) was shown to be a crucial cytokine for the initiation of a TH1 immune response. We aimed to investigate whether SPP1 single nucleotide polymorphisms (SNPs) may influence sustained virological response (SVR) rates. METHODS: Two SNPs in the promoter region of SPP1 at the -443 C>T and -1748 G>A loci were genotyped in 100 patients with chronic HCV genotype 4 infection using a TaqMan SNP genotyping assay. RESULTS: Sixty-seven patients achieved a SVR, and 33 patients showed no SVR. Patients carrying the T/T genotype at the -443 locus showed a significantly higher SVR rate than those carrying the C/T or C/C genotype (83.67% vs 50.98%, p<0.001). At the -1748 locus, the SVR rate was significantly higher in patients with the G/G genotype than in those with the A/A genotype (88.89% vs 52.63%, p=0.028) and in patients with the G/A genotype than in those with the A/A genotype (85.29% vs 52.63%, p=0.001). CONCLUSIONS: SPP1 SNPs at -443 C>T and -1748 G>A loci may be useful markers for predicting the response to PEG-IFN-alpha-2b plus RBV therapy in Egyptian patients with chronic HCV genotype 4 infection.
